PPA
CARM

Parametric Portfolio Associates’s Carisma Therapeutics CARM Stock Holding History

Parametric Portfolio Associates’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$21K Hold
1,749
– – ﹤0.01% 3660
2021
Q4 		$29K Sell
1,749
-1,031
-37% -$20.8K ﹤0.01% 3616
2021
Q3 		$44K Sell
2,780
-1,419
-34% -$68.1K ﹤0.01% 3581
2021
Q2 		$388K Buy
+4,199
New +$268K ﹤0.01% 3181

Other funds holding CARM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parametric Portfolio Associates's CARM Position: Q1 2022 in Review

Parametric Portfolio Associates held its Carisma Therapeutics (CARM) position steady in Q1 2022 at 1,749 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #3660.

Parametric Portfolio Associates first reported a position in CARM in Q2 2021 and has held it in 4 quarters since. The position peaked at $388K in Q2 2021. 84 funds tracked by Wall St. Rank hold CARM as of Q1 2022.

  • Parametric Portfolio Associates held 1,749 shares of Carisma Therapeutics worth $21K as of Q1 2022.
  • Parametric Portfolio Associates left its Carisma Therapeutics share count unchanged in Q1 2022.
  • Carisma Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3660 holding.
  • Parametric Portfolio Associates first reported a position in Carisma Therapeutics in Q2 2021 and has held it in 4 quarters since.
  • Parametric Portfolio Associates's Carisma Therapeutics position peaked at $388K in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.